Elevated ALDH1A1 expression is associated with poor 5-year overall survival for ovarian cancer patients51 as well as poor response to platinum-based therapy in patients with high-grade ovarian serous carcinoma52. Here, ALDH1A1 is linked to ovarian carcinoma.